Mount Yale Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19M Buy
87,277
+53,414
+158% +$11.8M 0.44% 47
2025
Q4
$7.74M Buy
33,863
+1,089
+3% +$248K 0.37% 55
2025
Q3
$7.59M Buy
32,774
+8,652
+36% +$1.76M 0.53% 41
2025
Q2
$4.48M Sell
24,122
-2,952
-11% -$549K 0.35% 51
2025
Q1
$5.67M Sell
27,074
-1,478
-5% -$287K 0.49% 29
2024
Q4
$5.07M Buy
28,552
+1,514
+6% +$278K 0.41% 39
2024
Q3
$5.34M Sell
27,038
-1,185
-4% -$221K 0.51% 35
2024
Q2
$4.84M Buy
28,223
+4,727
+20% +$783K 0.38% 52
2024
Q1
$4.28M Buy
23,496
+589
+3% +$102K 0.33% 69
2023
Q4
$3.55M Sell
22,907
-303
-1% -$44.2K 0.34% 75
2023
Q3
$3.46M Buy
23,210
+2,278
+11% +$334K 0.38% 60
2023
Q2
$2.82M Sell
20,932
-2,535
-11% -$372K 0.3% 76
2023
Q1
$3.74M Sell
23,467
-726
-3% -$111K 0.42% 54
2022
Q4
$3.91M Sell
24,193
-462
-2% -$70.8K 0.44% 59
2022
Q3
$3.31M Sell
24,655
-8,842
-26% -$1.27M 0.44% 53
2022
Q2
$5.13M Buy
33,497
+902
+3% +$138K 0.65% 35
2022
Q1
$5.28M Sell
32,595
-166
-0.5% -$24.1K 0.57% 39
2021
Q4
$4.44M Sell
32,761
-227
-0.7% -$26.8K 0.46% 50
2021
Q3
$3.56M Buy
32,988
+1,332
+4% +$152K 0.41% 62
2021
Q2
$3.57M Buy
31,656
+830
+3% +$93.5K 0.43% 55
2021
Q1
$3.34M Sell
30,826
-140
-0.5% -$15K 0.44% 55
2020
Q4
$3.32M Buy
30,966
+2,342
+8% +$225K 0.47% 55
2020
Q3
$2.51M Sell
28,624
-2,864
-9% -$270K 0.36% 69
2020
Q2
$3.09M Buy
31,488
+4,738
+18% +$417K 0.55% 47
2020
Q1
$2.04M Sell
26,750
-932
-3% -$79.4K 0.46% 53
2019
Q4
$2.24M Sell
27,682
-995
-3% -$82.6K 0.39% 58
2019
Q3
$2.48M Buy
28,677
+1,308
+5% +$89.7K 0.44% 56
2019
Q2
$1.76M Buy
27,369
+1,057
+4% +$83.1K 0.33% 76
2019
Q1
$2.12M Sell
26,312
-221
-0.8% -$18.1K 0.4% 61
2018
Q4
$2.12M Buy
26,533
+19,766
+292% +$1.74M 0.43% 55
2018
Q3
$588K Sell
6,767
-66,247
-91% -$6.28M 0.1% 153
2018
Q2
$6.76M Buy
73,014
+2,748
+4% +$268K 1.28% 19
2018
Q1
$6.65M Buy
+70,266
New +$7.72M 1.43% 11

Other funds holding ABBV

Mount Yale Investment Advisors's ABBV Position: Q1 2026 in Review

Mount Yale Investment Advisors increased its AbbVie (ABBV) stake by 158% in Q1 2026, buying an estimated $11.8M and bringing the position to 87,277 shares worth $19M. The position accounts for 0.44% of the portfolio, ranked #47.

Mount Yale Investment Advisors first reported a position in ABBV in Q1 2018 and has held it in 33 quarters since. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Mount Yale Investment Advisors held 87,277 shares of AbbVie worth $19M as of Q1 2026.
  • Mount Yale Investment Advisors bought 53,414 AbbVie shares in Q1 2026, an estimated $11.8M.
  • AbbVie made up 0.44% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #47 holding.
  • Mount Yale Investment Advisors first reported a position in AbbVie in Q1 2018 and has held it in 33 quarters since.
  • 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.